Phathom Pharmaceuticals PHAT 深 滬
等待開盤 04-03 09:30:00 美东时间
11.34
+0.200
+1.80%
華盛通- 最 高11.37
- 今 開10.91
- 成交量 78.63万股
- 最 低 10.80
- 昨 收 11.14
- 總市值 8.94亿
- 52周最高 18.31
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 2.21
- 委 比 -8.50%
- 總股本 7879.87万
- 歷史最高 64.54
- 量 比 0.68
- 振 幅 5.12%
- 歷史最低 2.21
- 每 手 1
- 風險率 3.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 price target. Check out analysts' views on these stocks.
03-27 21:25
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 27 (Reuters) - Wall Street's main indexes were on track to open lower
03-27 21:15
Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18
Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.
03-27 20:33
BUZZ- Barclays raises Phathom Pharmaceuticals to 'overweight'; shares rise
BUZZ- Barclays raises Phathom Pharmaceuticals to 'overweight'; shares rise ** Gastrointestinal (GI) diseases-focused biopharma Phathom Pharmaceuticals PHAT.O shares rise 2% to $11 premarket ** Barclays upgrades stock to "overweight" from "equal-weight" ** Brokerage raises target price to $18 from $1
03-27 19:12
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Phathom Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY26 sales guidance above estimates.
Phathom Pharmaceuticals shares are trading higher after the company reported be...
02-26 23:35
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million Feb 26 (Reuters) - Phathom Pharmaceuticals Q4 revenue USD 57.584 million vs. IBES estimate USD 57 million.
02-26 20:00
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026
Phathom Pharmaceuticals, Inc. will host a live webcast on February 26, 2026, at 8:00 am EST, to report its 2025 fourth quarter and full year financial results and provide a business update. The webcast and additional information can be accessed on its website. The company focuses on developing treatments for gastrointestinal diseases and markets vonoprazan-based products in the U.S.
02-17 13:00
